Transforming standards of care in cardiovascular treatments
Xeltis has raised €177M across 9 funding rounds from 16 investors, most recently a round in Jul 2026. Based in Zurich, Switzerland; founded 2006; active in Healthtech. Data as of 7 Aug 2026.
Timing: too soon vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2026-07-28 | Other | €19M | DaVita,EQT Life Sciences,European Innovation Council (EIC),existing shareholders,Horizon 3 Healthcare,Invest-NL+1 more | View deal → |
| 2023-08-14 | Other | €13M | European Innovation Council (EIC) Fund | View deal → |
| 2023-02-23 | Series D+ | €32M | DaVita Venture Group,EQT Life Sciences,Grand Pharma,international investors,Invest-NL | View deal → |
| 2022-08-09 | Series D+ | €15M | Grand Pharmaceutical Group | View deal → |
| 2021-11-29 | Other | €15M | European Investment Bank (EIB) | View deal → |
| 2019-10-01 | Series D+ | €11M | LSP | View deal → |
| 2017-11-16 | Other | €0 | — | View deal → |
| 2017-04-01 | Series C | €45M | Ysios Capital | View deal → |
| 2014-12-01 | Series B | €27M | Life Sciences Partners,VI Partners | View deal → |
